When 23andMe decided to stop offering health-related tests to new customers in early December, it may have created a 2014 consumer genomics market environment defined by what company can provide the best ancestry testing and genetic genealogy experience to its customers.
While the advent of Illumina's new 24-sample BeadChip format has meant that consumer genomics companies can double or triple their throughput, some genetic genealogists have voiced concerns about what impact these new arrays might have on ancestry testing.
This article was originally posted on Nov. 27. The US Food and Drug Administration's recent letter to consumer genomics firm 23andMe could have repercussions for the microarray industry's leading vendor.
Sometime earlier this year, the millionth person ordered a direct-to-consumer genetic test. Most likely, the test was ordered for ancestry or genetic genealogy purposes. It also was likely to have been run on a microarray manufactured by Illumina.